Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Glythera Ltd and the FDA enter into vaccine research collaboration agreementThe FDA is to assess the feasibility of Glythera technology in developing antigenic glycoproteins as synthetic conjugate vaccines.
By: Mark Warne Working with the Centre for Biologics Evaluation and Research at the FDA, Glythera will adapt its patented PermaLink technology to develop new chemistries for the simple and efficient attachment of antigenic carbohydrates, produced synthetically by the FDA, onto carrier proteins. To date there are a number of difficulties associated with the production of effective carbohydrate- “We are delighted to enter into this direct collaboration with the FDA” says Anthony Baxter, Chairman of Glythera. “This programme will allow us to demonstrate the versatility of our PermaLink technology for application in this important field of vaccine development” # # # About Glythera Glythera Ltd is a spin-out biotechnology company from the University of Bath, creating an improved generation of biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide functionalisation and glycosylation technologies, to impart improved pharmacokinetic properties such as increased half-life and stability, to a broader range of protein and peptide based therapeutics. End
Account Email Address Disclaimer Report Abuse
|
|